W
hen tumor necrosis factor (TNF) appeared on the cover of Time magazine in the mid-1980s, there were great hopes for this compound, which had dramatically shrunk tumors in mice. Those hopes evaporated when preclinical and phase I trials revealed profound side effects, such as life-threatening drops in blood pressure and liver toxicity.
But now TNF is making a comeback thanks to recent advances in nanotechnology. Steven Libutti, M.D., of Montefi ore -Einstein Center for Cancer Care in New York showed in a phase I clinical trial that high doses of TNF linked to gold nanoparticles could be safely given to 30 patients with various advanced solid tumors. In fact, the dose escalation trial never found a dose-limiting toxicity for the reformulated TNF, even at what previously was considered a lethal dose.
"We have mitigated the toxicity of a promising agent that for a long time was dismissed because it was too dangerous to give to patients," Libutti said. Plans are now under way for a phase II study of the gold-bound TNF in combination with a standard cytotoxic drug.
TNF is just one of several older toxic anticancer compounds, long ago shelved or little used, that researchers are now giving a second look. Driving this trend are second-generation nanotechnology products designed to deliver more potent but less toxic drugs to tumors.
"Big pharma produces tens of thousands of new chemical entities by medicinal chemistry, but the majority of those have to be disqualifi ed due to insolubility, toxicity, or so forth," said Scott McNeil, Ph.D., director of the National Cancer Institute's Nanotechnology Characterization Laboratory, speaking at a recent Institute of Medicine (IOM) workshop on nanotechnology and cancer. "Nanotechnology might be able to resurrect some of those drugs, because we can truly engineer properties into and out of those formulations."
Others, however, question whether cancer nanodrugs will truly be safer. The long-term effects of most new nanodrugs are not known, and with their unique features, the current battery of toxicology tests may not be suffi cient to fully assess their safety, these experts say.
Shielding the Body
Cancer nanodrugs made their debut with liposome-encased doxorubicin (Doxil), which was easier on the heart than its naked predecessor and has been on the market for about 15 years. The secondgeneration nanodrugs tend to be smaller, have added targeting agents, combine multiple drugs, or use encapsulation or carrier materials that are more fi ne-tuned to better deliver the drugs only to their targets. All these features make the next generation of nanodrugs especially likely to concentrate in tumor tissues, thus enabling larger doses of the drugs to be safely given to patients or allowing smaller doses to be more potent.
For nab -paclitaxel -paclitaxel attached to the protein carrier albumin -clinical trials show not only that the maximum tolerated dose is about twice that for paclitaxel alone but also that it is substantially more effective. And it does not require preadministration with a steroid and antihistamines to prevent severe reactions.
The U.S. Food and Drug Administration approved nab -paclitaxel for breast cancer treatment in 2005, and a phase III trial recently showed that the drug given with carboplatin was statistically signifi cantly more effective than standard paclitaxel and carboplatin in non -small-cell lung cancer. Patients given Nab -paclitaxel had a 33% overall response rate by independent radiologic review, whereas those given standard paclitaxel had a 25% overall response rate. Mark Socinski, M.D., oncologist and associate professor at the University of North Carolina at Chapel Hill, presented the results last June at the annual meeting of the American Society of Clinical Oncology. Nab -paclitaxel is also in a phase II trial in patients with pancreatic cancer or melanoma, according to Neil Desai, Ph.D., vice president of research and development at Abraxis Bioscience.
Several drug companies have also developed various types of liposomal or polymer packaging for standard cytotoxic drugs, including cisplatin, oxaliplatin, and methotrexate. Some of these nanocarriers are designed to evade the immune system and factors that foster their rapid elimination from the body, thereby increasing their circulation and possibly their effectiveness. These nanoversions of standard chemotherapeutic drugs are in clinical trials for solid tumors, such as stomach, lung, and pancreatic cancer, according to the websites of the companies that produce them. These companies include NanoCarrier, based in Japan, and Regulon, incorporated in both California and Europe.
Better concentration in tumors is the aim of cancer drugs whose nanocarriers are decorated with targeting agents. BIND Bioscience, for example, has a version of docetaxel that is ferried to tumors by a polymer nanoparticle dotted with homing molecules that target prostate-specifi c membrane antigen. Both prostate tumors and the blood vessels that feed other solid tumors express this antigen. In animal studies, targeting this protein led to as much as a 20-fold increase in the concentration of the drug in prostate or lung cancer tissue. It also fostered a more effective tumor response than that of the standard drug or the polymer carrier version of the drug without the targeting proteins, according to Omid Farokhzad, M.D., associate professor at the Harvard Medical School and one of the founders of BIND Bioscience. The company expects to start clinical trials of the compound shortly.
Other researchers, such as Libutti, are linking metallic nanoparticles to cancer drugs, banking on the specialized features of these particles that make them especially suited to deliver cancer medicines ( see sidebar). In addition to using gold to deliver TNF, researchers are exploring its use as a drug ferry for more established cancer therapeutics, such as oxaliplatin. Some investigators have boosted the effectiveness of these metal-based nanodrugs in animal models by using a magnetic fi eld or infrared laser energy to heat up the metal carriers, thereby combining drug therapy with hyperthermia.
Safer in the Long Run?
Most nanodrugs using standard cytotoxic drugs are specifi cally designed to be safer than their predecessors and have proven less toxic in clinical trials to date. "We are lowering the toxicity of really nasty drugs. This is something that should be celebrated," said James Heath, Ph.D., of the California Institute of Technology, at the IOM workshop. But others sound a more cautious note. Most nanodrugs on the market so far are made of biocompatible materials and are relatively simple constructs. By contrast, many of those in company pipelines have more components, and their biocompatibility is either not known or suspect, according to King Li, M.D., a radiologist and professor at the Weill Cornell Medical College in New York and Methodist Hospital in Houston.
"Yes, nanotechnology is a very exciting fi eld with a lot of potential, but on the fl ip side, there are things we need to consider that can make them potentially harmful," he said. "We need to make those considerations up front before we waste a lot of energy, because you can be causing problems before you even know it, and we don't want to do more harm than good." Among those considerations is the binding of nanomaterials to proteins in the body, which impedes the nanomaterials ' excretion and metabolism. Such protein binding can also elicit immune reac tions. Li is concerned, for example, about nanoparticles ' taking up long-term lodging in the lungs after inhalation. Once in the lungs, they could act as persistent irritants that, like asbestos, go on to cause longterm problems.
The standard battery of toxicology and biodistribution testswhich measure mainly acute and not chronic effects -could miss such problems. At the IOM conference, Yuliang Zhao, Ph.D., founder of the Chinese Academy of Sciences Nanosafety Lab, said that his Why Nanocarriers?
Nanomaterials have several features that make them especially adept at ferrying anticancer compounds to tumors:
• The "Goldilocks effect": Nanodrugs are large enough that they aren't rapidly eliminated through the kidney yet small enough that they are more likely to penetrate leaky blood vessels that feed tumors and then get trapped in tumor tissue.
• Nanoparticles are more likely to enter a cell by endocytosis, which protects the particle's payload from being ejected by cellular pumps known to confer drug resistance. Because they can enter cells, nanoparticles are useful carriers for drugs that operate intracellularly, such as interference RNA. Researchers have developed a nanocarrier for silencing RNA that recently completed phase I testing for certain cancers.
• The surfaces of nanoparticles have much available room to attach compounds, such as antigens and other proteins, which further target nanodrugs to tumors or the blood vessels that feed them. Nanoparticles can also incorporate multiple drugs, making combination therapy possible on a single platform. Researchers have developed nanoparticles that deliver two or more anticancer drugs simultaneously and completed tests in animal models.
